APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody for Gastric Cancer

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Monoclonal Antibody for Gastric Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025185 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody for Gastric Cancer Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody for Gastric Cancer Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody for Gastric Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody for Gastric Cancer Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody for Gastric Cancer Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Monoclonal Antibody for Gastric Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Monoclonal Antibody for Gastric Cancer is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Monoclonal Antibody for Gastric Cancer include Innovent Biologics, Inc, Henlius, Merck & Co., Inc, Eli Lilly & Co, CStone Pharmaceuticals, Astellas Pharma, Inc., Genentech, Bristol Myers Squibb Co and BeiGene Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Monoclonal Antibody for Gastric Cancer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Monoclonal Antibody for Gastric Cancer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Monoclonal Antibody for Gastric Cancer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Monoclonal Antibody for Gastric Cancer market size, projected growth trends, production technologies, key applications, and end-use industries.

Monoclonal Antibody for Gastric Cancer Segment by Company

Innovent Biologics, Inc

Henlius

Merck & Co., Inc

Eli Lilly & Co

CStone Pharmaceuticals

Astellas Pharma, Inc.

Genentech

Bristol Myers Squibb Co

BeiGene Ltd

Monoclonal Antibody for Gastric Cancer Segment by Type

5 mg/mL

4 mg/mL

10 mg/mL

Monoclonal Antibody for Gastric Cancer Segment by Application

Hospital

Clinic

Others

Monoclonal Antibody for Gastric Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody for Gastric Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody for Gastric Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody for Gastric Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Monoclonal Antibody for Gastric Cancer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Monoclonal Antibody for Gastric Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Monoclonal Antibody for Gastric Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Monoclonal Antibody for Gastric Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Monoclonal Antibody for Gastric Cancer Industry Trends Table 2. Monoclonal Antibody for Gastric Cancer Industry Drivers Table 3. Monoclonal Antibody for Gastric Cancer Industry Opportunities and Challenges Table 4. Monoclonal Antibody for Gastric Cancer Industry Restraints Table 5. Global Monoclonal Antibody for Gastric Cancer Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Monoclonal Antibody for Gastric Cancer Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Manufacturers Table 9. Global Monoclonal Antibody for Gastric Cancer Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Monoclonal Antibody for Gastric Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Monoclonal Antibody for Gastric Cancer Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Monoclonal Antibody for Gastric Cancer Manufacturers, Product Type & Application Table 13. Global Monoclonal Antibody for Gastric Cancer Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Monoclonal Antibody for Gastric Cancer by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 5 mg/mL Table 17. Major Manufacturers of 4 mg/mL Table 18. Major Manufacturers of 10 mg/mL Table 19. Global Monoclonal Antibody for Gastric Cancer Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Monoclonal Antibody for Gastric Cancer Sales by Type (2021-2026) & (K Units) Table 21. Global Monoclonal Antibody for Gastric Cancer Sales by Type (2027-2032) & (K Units) Table 22. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2021-2026) Table 23. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2027-2032) Table 24. Global Monoclonal Antibody for Gastric Cancer Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2021-2026) & (K Units) Table 26. Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2027-2032) & (K Units) Table 27. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2021-2026) Table 28. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Others Table 32. Global Monoclonal Antibody for Gastric Cancer Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Monoclonal Antibody for Gastric Cancer Sales by Application (2021-2026) & (K Units) Table 34. Global Monoclonal Antibody for Gastric Cancer Sales by Application (2027-2032) & (K Units) Table 35. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2021-2026) Table 36. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2027-2032) Table 37. Global Monoclonal Antibody for Gastric Cancer Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2021-2026) & (K Units) Table 39. Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2027-2032) & (K Units) Table 40. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2021-2026) Table 41. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2027-2032) Table 42. Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Monoclonal Antibody for Gastric Cancer Sales by Region (2021-2026) & (K Units) Table 44. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Region (2021-2026) Table 45. Global Monoclonal Antibody for Gastric Cancer Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Monoclonal Antibody for Gastric Cancer Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2026) & (K Units) Table 49. North America Monoclonal Antibody for Gastric Cancer Sales by Country (2027-2032) & (K Units) Table 50. Europe Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2026) & (K Units) Table 52. Europe Monoclonal Antibody for Gastric Cancer Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (2027-2032) & (K Units) Table 59. Global Monoclonal Antibody for Gastric Cancer Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Monoclonal Antibody for Gastric Cancer Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Monoclonal Antibody for Gastric Cancer Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2021-2026) Table 63. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2027-2032) Table 64. Innovent Biologics, Inc Company Information Table 65. Innovent Biologics, Inc Business Overview Table 66. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product Portfolio Table 68. Innovent Biologics, Inc Recent Development Table 69. Henlius Company Information Table 70. Henlius Business Overview Table 71. Henlius Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Henlius Monoclonal Antibody for Gastric Cancer Product Portfolio Table 73. Henlius Recent Development Table 74. Merck & Co., Inc Company Information Table 75. Merck & Co., Inc Business Overview Table 76. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product Portfolio Table 78. Merck & Co., Inc Recent Development Table 79. Eli Lilly & Co Company Information Table 80. Eli Lilly & Co Business Overview Table 81. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product Portfolio Table 83. Eli Lilly & Co Recent Development Table 84. CStone Pharmaceuticals Company Information Table 85. CStone Pharmaceuticals Business Overview Table 86. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product Portfolio Table 88. CStone Pharmaceuticals Recent Development Table 89. Astellas Pharma, Inc. Company Information Table 90. Astellas Pharma, Inc. Business Overview Table 91. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product Portfolio Table 93. Astellas Pharma, Inc. Recent Development Table 94. Genentech Company Information Table 95. Genentech Business Overview Table 96. Genentech Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Genentech Monoclonal Antibody for Gastric Cancer Product Portfolio Table 98. Genentech Recent Development Table 99. Bristol Myers Squibb Co Company Information Table 100. Bristol Myers Squibb Co Business Overview Table 101. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product Portfolio Table 103. Bristol Myers Squibb Co Recent Development Table 104. BeiGene Ltd Company Information Table 105. BeiGene Ltd Business Overview Table 106. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product Portfolio Table 108. BeiGene Ltd Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Monoclonal Antibody for Gastric Cancer Distributors List Table 112. Monoclonal Antibody for Gastric Cancer Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Monoclonal Antibody for Gastric Cancer Product Image Figure 2. Global Monoclonal Antibody for Gastric Cancer Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Monoclonal Antibody for Gastric Cancer Market Size (2021-2032) & (US$ Million) Figure 4. Global Monoclonal Antibody for Gastric Cancer Sales (2021-2032) & (K Units) Figure 5. Global Monoclonal Antibody for Gastric Cancer Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Monoclonal Antibody for Gastric Cancer Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 5 mg/mL Image Figure 9. 4 mg/mL Image Figure 10. 10 mg/mL Image Figure 11. Global Monoclonal Antibody for Gastric Cancer Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Monoclonal Antibody for Gastric Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2021-2032) Figure 14. Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Monoclonal Antibody for Gastric Cancer Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Monoclonal Antibody for Gastric Cancer Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2021-2032) Figure 23. Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2021-2032) Figure 26. North America Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021-2032) Figure 28. U.S. Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021-2032) Figure 33. Germany Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021-2032) Figure 40. China Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales Market Share by Country (2021-2032) Figure 48. Brazil Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Monoclonal Antibody for Gastric Cancer Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Monoclonal Antibody for Gastric Cancer Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Monoclonal Antibody for Gastric Cancer Revenue (2021-2032) & (US$ Million) Figure 59. North America Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Monoclonal Antibody for Gastric Cancer Revenue (2021-2032) & (US$ Million) Figure 61. Europe Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Monoclonal Antibody for Gastric Cancer Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Monoclonal Antibody for Gastric Cancer Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Monoclonal Antibody for Gastric Cancer Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 5 mg/mL
  • 4 mg/mL
  • 10 mg/mL
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Innovent Biologics, Inc
  • Henlius
  • Merck & Co., Inc
  • Eli Lilly & Co
  • CStone Pharmaceuticals
  • Astellas Pharma, Inc.
  • Genentech
  • Bristol Myers Squibb Co
  • BeiGene Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Monoclonal Antibody for Gastric Cancer Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Monoclonal Antibody for Gastric Cancer Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Monoclonal Antibody for Gastric Cancer Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Monoclonal Antibody for Gastric Cancer Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Monoclonal Antibody for Gastric Cancer Market Dynamics
  1. 2.1 Monoclonal Antibody for Gastric Cancer Industry Trends
  2. 2.2 Monoclonal Antibody for Gastric Cancer Industry Drivers
  3. 2.3 Monoclonal Antibody for Gastric Cancer Industry Opportunities and Challenges
  4. 2.4 Monoclonal Antibody for Gastric Cancer Industry Restraints
3 Monoclonal Antibody for Gastric Cancer Market by Manufacturers
  1. 3.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Monoclonal Antibody for Gastric Cancer Sales by Manufacturers (2021-2026)
  3. 3.3 Global Monoclonal Antibody for Gastric Cancer Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Monoclonal Antibody for Gastric Cancer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Monoclonal Antibody for Gastric Cancer Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Monoclonal Antibody for Gastric Cancer Manufacturers, Product Type & Application
  7. 3.7 Global Monoclonal Antibody for Gastric Cancer Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Monoclonal Antibody for Gastric Cancer Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Monoclonal Antibody for Gastric Cancer Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Monoclonal Antibody for Gastric Cancer Tier 1, Tier 2, and Tier 3
4 Monoclonal Antibody for Gastric Cancer Market by Type
  1. 4.1 Monoclonal Antibody for Gastric Cancer Type Introduction
  2. 4.1.1 5 mg/mL
  3. 4.1.2 4 mg/mL
  4. 4.1.3 10 mg/mL
  5. 4.2 Global Monoclonal Antibody for Gastric Cancer Sales by Type
  6. 4.2.1 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Monoclonal Antibody for Gastric Cancer Sales by Type (2021-2032)
  8. 4.2.3 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Type (2021-2032)
  9. 4.3 Global Monoclonal Antibody for Gastric Cancer Revenue by Type
  10. 4.3.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Type (2021-2032)
  12. 4.3.3 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Type (2021-2032)
5 Monoclonal Antibody for Gastric Cancer Market by Application
  1. 5.1 Monoclonal Antibody for Gastric Cancer Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Monoclonal Antibody for Gastric Cancer Sales by Application
  6. 5.2.1 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Monoclonal Antibody for Gastric Cancer Sales by Application (2021-2032)
  8. 5.2.3 Global Monoclonal Antibody for Gastric Cancer Sales Market Share by Application (2021-2032)
  9. 5.3 Global Monoclonal Antibody for Gastric Cancer Revenue by Application
  10. 5.3.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Application (2021-2032)
  12. 5.3.3 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Application (2021-2032)
6 Global Monoclonal Antibody for Gastric Cancer Sales by Region
  1. 6.1 Global Monoclonal Antibody for Gastric Cancer Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Monoclonal Antibody for Gastric Cancer Sales by Region (2021-2032)
  3. 6.2.1 Global Monoclonal Antibody for Gastric Cancer Sales by Region (2021-2026)
  4. 6.2.2 Global Monoclonal Antibody for Gastric Cancer Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Monoclonal Antibody for Gastric Cancer Revenue by Region
  1. 7.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Region
  2. 7.1.1 Global Monoclonal Antibody for Gastric Cancer Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Monoclonal Antibody for Gastric Cancer Revenue by Region (2021-2026)
  4. 7.1.3 Global Monoclonal Antibody for Gastric Cancer Revenue by Region (2027-2032)
  5. 7.1.4 Global Monoclonal Antibody for Gastric Cancer Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Monoclonal Antibody for Gastric Cancer Revenue (2021-2032)
  8. 7.2.2 North America Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Monoclonal Antibody for Gastric Cancer Revenue (2021-2032)
  11. 7.3.2 Europe Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Monoclonal Antibody for Gastric Cancer Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Monoclonal Antibody for Gastric Cancer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Innovent Biologics, Inc
  2. 8.1.1 Innovent Biologics, Inc Company Information
  3. 8.1.2 Innovent Biologics, Inc Business Overview
  4. 8.1.3 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Innovent Biologics, Inc Monoclonal Antibody for Gastric Cancer Product Portfolio
  6. 8.1.5 Innovent Biologics, Inc Recent Developments
  7. 8.2 Henlius
  8. 8.2.1 Henlius Company Information
  9. 8.2.2 Henlius Business Overview
  10. 8.2.3 Henlius Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Henlius Monoclonal Antibody for Gastric Cancer Product Portfolio
  12. 8.2.5 Henlius Recent Developments
  13. 8.3 Merck & Co., Inc
  14. 8.3.1 Merck & Co., Inc Company Information
  15. 8.3.2 Merck & Co., Inc Business Overview
  16. 8.3.3 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc Monoclonal Antibody for Gastric Cancer Product Portfolio
  18. 8.3.5 Merck & Co., Inc Recent Developments
  19. 8.4 Eli Lilly & Co
  20. 8.4.1 Eli Lilly & Co Company Information
  21. 8.4.2 Eli Lilly & Co Business Overview
  22. 8.4.3 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly & Co Monoclonal Antibody for Gastric Cancer Product Portfolio
  24. 8.4.5 Eli Lilly & Co Recent Developments
  25. 8.5 CStone Pharmaceuticals
  26. 8.5.1 CStone Pharmaceuticals Company Information
  27. 8.5.2 CStone Pharmaceuticals Business Overview
  28. 8.5.3 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CStone Pharmaceuticals Monoclonal Antibody for Gastric Cancer Product Portfolio
  30. 8.5.5 CStone Pharmaceuticals Recent Developments
  31. 8.6 Astellas Pharma, Inc.
  32. 8.6.1 Astellas Pharma, Inc. Company Information
  33. 8.6.2 Astellas Pharma, Inc. Business Overview
  34. 8.6.3 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Astellas Pharma, Inc. Monoclonal Antibody for Gastric Cancer Product Portfolio
  36. 8.6.5 Astellas Pharma, Inc. Recent Developments
  37. 8.7 Genentech
  38. 8.7.1 Genentech Company Information
  39. 8.7.2 Genentech Business Overview
  40. 8.7.3 Genentech Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genentech Monoclonal Antibody for Gastric Cancer Product Portfolio
  42. 8.7.5 Genentech Recent Developments
  43. 8.8 Bristol Myers Squibb Co
  44. 8.8.1 Bristol Myers Squibb Co Company Information
  45. 8.8.2 Bristol Myers Squibb Co Business Overview
  46. 8.8.3 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol Myers Squibb Co Monoclonal Antibody for Gastric Cancer Product Portfolio
  48. 8.8.5 Bristol Myers Squibb Co Recent Developments
  49. 8.9 BeiGene Ltd
  50. 8.9.1 BeiGene Ltd Company Information
  51. 8.9.2 BeiGene Ltd Business Overview
  52. 8.9.3 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BeiGene Ltd Monoclonal Antibody for Gastric Cancer Product Portfolio
  54. 8.9.5 BeiGene Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Monoclonal Antibody for Gastric Cancer Value Chain Analysis
  2. 9.1.1 Monoclonal Antibody for Gastric Cancer Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Monoclonal Antibody for Gastric Cancer Production Mode & Process
  6. 9.2 Monoclonal Antibody for Gastric Cancer Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Monoclonal Antibody for Gastric Cancer Distributors
  9. 9.2.3 Monoclonal Antibody for Gastric Cancer Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst